Page 34 - Read Online

Frame et al. Investigating models for prostate cancer research

cancer: emerging appreciation of genetic complexity. Histopathology P. Establishment and characterization of an immortalized but non-
2012;60:187-98. transformed human prostate epithelial cell line: BPH-1. In Vitro Cell
4. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde Dev Biol Anim 1995;31:14-24.
E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, 12. Maitland NJ, Macintosh CA, Hall J, Sharrard M, Quinn G, Lang S. In
Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, vitro models to study cellular differentiation and function in human
Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson prostate cancers. Radiat Res 2001;155:133-42.
JD, Simmons TT, P’ng C, Zafarana G, Nguyen F, Luo X, Chu KC, 13. Frame FM, Pellacani D, Collins AT, Maitland NJ. Harvesting human
Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue prostate tissue material and culturing primary prostate epithelial cells.
MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Methods Mol Biol 2016;1443:181-201.
Starmans MH, Chen H, Govind SK, Hawley J, D’Costa A, Pintilie M, 14. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and
Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, isolation of human prostate epithelial stem cells based on alpha(2)
Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins beta(1)-integrin expression. J Cell Sci 2001;114:3865-72.
CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG. Spatial 15. Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM,
genomic heterogeneity within localized, multifocal prostate cancer. Jones GD, Meuth M, Bristow RG, Maitland NJ. HDAC inhibitor
Nat Genet 2015;47:736-45. confers radiosensitivity to prostate stem-like cells. Br J Cancer
5. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, 2013;109:3023-33.
pathological, and clinical heterogeneity as drivers of personalized 16. Sturmey RG, Hawkhead JA, Barker EA, Leese HJ. DNA damage
medicine in prostate cancer. Urol Oncol 2015;33:85-94. and metabolic activity in the preimplantation embryo. Hum Reprod
6. Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez 2009;24:81-91.
EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari 17. Kasprowicz R, Suman R, O’Toole P. Characterising live cell
G, Mohler JL, Liu S, Heemers HV. Intratumoral and intertumoral behaviour: traditional label-free and quantitative phase imaging
genomic heterogeneity of multifocal localized prostate cancer impacts approaches. Int J Biochem Cell Biol 2017;84:89-95.
molecular classifications and genomic prognosticators. Eur Urol 18. Marrison J, Raty L, Marriott P, O’Toole P. Ptychography -- a label
2017;71:183-92. free, high-contrast imaging technique for live cells using quantitative
7. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, phase information. Sci Rep 2013;3:2369.
MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, 19. Suman R, Smith G, Hazel KE, Kasprowicz R, Coles M, O’Toole P,
Stephens PJ, Mosquera JM, Cronin MT, Rubin MA. Targeted Chawla S. Label-free imaging to study phenotypic behavioural traits
next-generation sequencing of advanced prostate cancer identifies of cells in complex co-cultures. Sci Rep 2016;6:22032.
potential therapeutic targets and disease heterogeneity. Eur Urol 20. Frame FM, Savoie H, Bryden F, Giuntini F, Mann VM, Simms MS,
2013;63:920-6. Boyle RW, Maitland NJ. Mechanisms of growth inhibition of primary
8. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier prostate epithelial cells following gamma irradiation or photodynamic
Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, therapy include senescence, necrosis, and autophagy, but not
Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair apoptosis. Cancer Med 2016;5:61-73.
D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri 21. Yan J, Tang D. Prostate cancer stem-like cells proliferate slowly and
CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos resist etoposide-induced cytotoxicity via enhancing DNA damage
AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, response. Exp Cell Res 2014;328:132-42.
Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz 22. Risbridger GP, Taylor RA. Patient-derived prostate cancer: from basic
G, Demichelis F, Rubin MA, Garraway LA. Punctuated evolution of science to the clinic. Horm Cancer 2016;7:236-40.
prostate cancer genomes. Cell 2013;153:666-77. 23. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective
9. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov identification of tumorigenic prostate cancer stem cells. Cancer Res
LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, 2005;65:10946-51.
Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, 24. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a
Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, compendium of old and new lines -- part 2. J Urol 2005;173:360-72.
Ramakrishna M, O’Meara S, Matthews L, Clark J, Hurst R, Mithen 25. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a
R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, compendium of old and new lines -- part 1. J Urol 2005;173:342-59.
Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, 26. Ulukaya E, Frame FM, Cevatemre B, Pellacani D, Walker H, Mann
Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison VM, Simms MS, Stower MJ, Yilmaz VT, Maitland NJ. Differential
M, Gamble S, Greenman C, Berney D, Hazell S, Livni N, Group IP, cytotoxic activity of a novel palladium-based compound on prostate
Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol cell lines, primary prostate epithelial cells and prostate stem cells.
D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, PLoS One 2013;8:e64278.
Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, 27. Hirst AM, Simms MS, Mann VM, Maitland NJ, O’Connell D, Frame
Whitaker HC, McDermott U, Brewer DS, Neal DE. Analysis of the FM. Low-temperature plasma treatment induces DNA damage leading
genetic phylogeny of multifocal prostate cancer identifies multiple to necrotic cell death in primary prostate epithelial cells. Br J Cancer
independent clonal expansions in neoplastic and morphologically 2015;112:1536-45.
normal prostate tissue. Nat Genet 2015;47:367-72. 28. Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS,
10. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Davies BR, Collins AT, Maitland NJ. Inhibition of the PI3K/AKT/
Papaemmanuil E, Brewer DS, Kallio HM, Hognas G, Annala M, mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/
Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs ERK signalling in prostate cancer. Oncotarget 2017;8:56698-713.
W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, 29. Pellacani D, Kestoras D, Droop AP, Frame FM, Berry PA,
Whitaker HC, Group IPU, Neal DE, Cooper CS, Eeles RA, Visakorpi Lawrence MG, Stower MJ, Simms MS, Mann VM, Collins AT,
T, Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary Risbridger GP, Maitland NJ. DNA hypermethylation in prostate
history of lethal metastatic prostate cancer. Nature 2015;520:353-7. cancer is a consequence of aberrant epithelial differentiation and
11. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan hyperproliferation. Cell Death Differ 2014;21:761-73.
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 6, 2017 313